Friday, 3 May 2013

The history of genetic engineering


Genetic Engineering
(1970-1990)


By the end of the 20th century, scientists were routinely trans. planting genes between organisms. shutting them down to study their functions, and manipulating them in many other ways. These technologies were being applied to the production of new foods and medicines, and many other uses could be foreseen. Bactena might be specially engineered to clean up oil spills or other types of pollution, artificial viruses might deliver healthy DNA to people suffering From genetic illnesses, and the body’s immune system could be reprogrammed to fight off cancer and other diseases. At the same time, genetic engineering is constantly presented as a scary topic in the headlines. A few examplesfrom 2007 were Franken.Broccolic The GM Seed Giants lumber into the Vcggic Latch.” from the December 19 issue of Gristmagazine; ‘Attack of the Mutant Biotech Rice,” from the July 9 issue of Fortune; and Generically Engineered Organisms Inv
ade Our Planet.” printed in the Epoch Times of March 12. What headlines usually fail to capture is the fact that genetic engineering has been a crucial tool in answering Fundamental questions about life. Genetic engineering was made possible by the development of new forms of biotechnology. This chapter describes how work carried out between the 1970s and 1990s produced an extremely Restriction enzymes are DNA cutting molecules from bacteria that are used as tools in genetic engineering. The enzymes recognize particular DNA sequences and break the strand, leaving two sticky ends. Other molecules recognize that the broken ends match and can mend them. If researchers create an artificial molecule with broken, sticky ends that match such breaks, the repair molecules may paste it into an organism’s genome.

Genetic Engineering from (1970-1990)


Genetic Engineering
(1970-1990)

By the end of the 20th century, scientists were routinely trans. planting genes between organisms. shutting them down to study their functions, and manipulating them in many other ways. These technologies were being applied to the production of new foods and medicines, and many other uses could be foreseen. Bactena might be specially engineered to clean up oil spills or other types of pollution, artificial viruses might deliver healthy DNA to people suffering From genetic illnesses, and the body’s immune system could be reprogrammed to fight off cancer and other diseases. At the same time, genetic engineering is constantly presented as a scary topic in the headlines. A few examplesfrom 2007 were Franken.Broccolic The GM Seed Giants lumber into the Vcggic Latch.” from the December 19 issue of Gristmagazine; ‘Attack of the Mutant Biotech Rice,” from the July 9 issue of Fortune; and Generically Engineered Organisms Inv
ade Our Planet.” printed in the Epoch Times of March 12. What headlines usually fail to capture is the fact that genetic engineering has been a crucial tool in answering Fundamental questions about life. Genetic engineering was made possible by the development of new forms of biotechnology. This chapter describes how work carried out between the 1970s and 1990s produced an extremely

The toxic algae and No-Till-The environmental Darling industrial agriculture and genetic engineering is less attractive

The toxic algae and No-Till-The environmental Darling industrial agriculture and genetic engineering is less attractive :  

Read attempts to defend the sustainability of industrial agriculture and genetic engineering, and you soon find yourself without tillage, or more generally, conservation tillage. It now appears that tillage can contribute to serious environmental problems.

Massive algal bloom, green, spreading across Lake Erie. NASA photo.

Tillage or tillage, is the ancient practice of turning the soil to kill weeds or incorporating plant material or manure. Tillage but often leads to increased soil erosion and loss of fertility. Erosion also contributes to the settling of phosphorus flows carrying the ground, a major cause of contamination of fresh water. So conservation tillage and direct seeding, in particular, have some real benefits, especially for industrial agriculture, which depletes soil fertility.

And soil fertility, in turn, is vital to ensure the productivity and resilience of crops.

We know that, while providing some real benefits, conservation tillage also has important limitations compared with agroecological approaches that reduce erosion, such as the growth of cover crops. Cover crops are grown to protect the soil in crops like maize are not present in the fall, winter and spring. They not only greatly reduce erosion and improve soil fertility, but also substantially reduce nitrogen loss caused by water pollution, such as dead zones in coastal areas. They can also suppress weeds and other pests, and reduce the need for synthetic fertilizers and pesticides. Conservation tillage provides none of these other benefits.

Another possible benefit of conservation tillage, the largest carbon capture is unproven. There may be providing some additional carbon capture some types of soils and climates compared to conventional tillage, but that remains to be seen. Furthermore, organic and related methods may not reliably increase soil carbon sequestration.

Toxic Slime
And now, new research reveals a darker side of the till, which can actually aggravate phosphorus pollution of waterways.

I grew up in Michigan, the heart of the Great Lakes region. These lakes, the largest in the world, are a wonder of nature that are more like freshwater seas. The lakes are an excellent resource for recreation, from swimming to fishing to boating. The Great Lakes have also had important commercial fisheries whitefish and other species. There has even been the Great Lakes cruises. The presence of lakes, including the smaller lakes in the region that extends from the Canadian prairies of the Midwest through upstate New York, greatly improves the quality of life and supports tourism.

He learns that the green slime cyanobacteria (sometimes called blue-green algae) was back with a vengeance was a shock. Efforts to reduce phosphorus plant wastewater treatment and laundry detergents in the 60s and 70s led to one of the real successes of the environmental movement. Lake Erie is particularly susceptible because they are relatively shallow. But in general are vulnerable lakes, smaller lakes and reservoirs, possibly even more. So although detected in Lake Erie, also happening elsewhere. For example, Lake Winnipeg, a large lake in Canada, is also seeing increasing eutrophication.

And the problems go beyond an eyesore cause odors or missing or fish kills. Two major species of cyanobacterial neurotoxins liver or products, found in the lake to alarming levels.

Lake Erie algal bloom of 2011 set records, reaching nearly 5,000 square miles, or about 3 times that of the next largest flowering. However, records show that algal blooms have increased since the mid-1990s, after several decades of progress.

What happened? Why the drive towards cleaner water reversed?

Direct seeding and climate change: a bad combination
The increase in harmful algal blooms coincides with the increasing use of direct seeding in the corn belt. It turns out that no-till, apply phosphorus fertilizer and phosphorus in manure is concentrated in the topsoil. Although direct seeding reduces runoff and soil erosion, which leads phosphorus bound to soil particles into waterways, resulting high concentration of phosphorus in the soil surface leads to runoff dissolved reactive phosphorus. Algal blooms resulting from this are compounded by heavy rains, which wash more phosphorus in the lake, which is expected to be more frequent in the region as global warming progresses.

Besides that, the phosphorus may become scarce in the future. Large deposits are found in only a few locations worldwide. Therefore, the loss of phosphorus from agricultural soils is also a waste of a valuable resource.

Tillage may occasionally help alleviate this problem, by burying the match. But it is clear that many forms of farming, such as the use of chisel plows cultivators or not invert the soil, or methods such as tillage or ridge rotation until, and so on, will address the problem effectively. And the data are scarce on whether the other benefits of direct seeding also be reduced in the process. Furthermore, most of the maize area still do not use direct seeding or conservation tillage, so it is possible that greater adoption could make things worse.

One lesson from this is that reductionist approaches to environmental problems that almost focus on solving a problem, such as soil erosion, without understanding the agricultural ecosystem are vulnerable to lack of harmful unintended consequences. Direct seeding is a valuable practice in some aspects, but as used in industrial agriculture, which relies on heavy use of herbicides, which causes its damage to agroecosystems, such as loss of habitat of the monarch butterfly, bees and other beneficial organisms.

It is also important to remember that other agro-based practices such as cover crops can achieve the benefits of direct seeding and more. Not only that, but no-till organic can also be practiced without the use of herbicides.

But it is no coincidence that the industry no-till has been a popular practice as a rhetorical tool ag community and industry. Fits the highly simplified and unsustainable system that big ag industry wants to keep. It is one of the few large ag practices that can promote that has some environmental benefits. And unlike agroecology, which depends on the products purchased expensive. That's good for the profitability of the industry, but not so good for the rest of us.

Posted in: Agriculture & Food Tags: agriculture, climate change, cover crops, genetic engineering, GMO, industrial agriculture, Lake Erie, phosphorus, sustainable agriculture, toxic algae, water pollution
About the author: Doug Gurian-Sherman is a widely cited expert on biotechnology and sustainable agriculture. He holds a Ph.D. in plant pathology. Subscribe to entries Doug

Support from UCS members make work like this possible. Want to join us? Help UCS advance independent science for a healthy environment and a safer world.

Genetic engineering ... good or bad?

Genetic engineering ... good or bad? :



Have you ever heard of genetic engineering? According to dictionary.com, genetic engineering is "the use of various methods to manipulate the DNA (genetic material) of cells to change hereditary traits or produce biological products." Over the years, scientists have been researching and trying different ways to use bioengineering. So far, they have managed to create medicinal eggs and bananas, goats that produce spider web proteins in their milk, and cats, even brilliant. You may have seen the genetic engineering work itself in certain foods such as beans, corn and tomatoes that are made to last for long periods of time. Genetic engineering has created wonderful things for humanity, but what is the right thing to do?

Most of the inventions that have come out of genetic engineering is supposed to have beneficial effects, but some people think that the manipulation of nature can disrupt the balanced system of life. For example, the virus that once affected by drugs such as antibiotics are evolving to medications like antibiotics have been overused and may not be effective. In addition, genetic engineering could add more allergens into the food supply. For example, if a certain food should be raised with a common allergen such as peanuts, new product, genetically altered may cause an allergic reaction in a person with a peanut allergy.

In my opinion, genetic engineering is a good thing. Genetic engineering has created the things that people have only dreamed. Thanks to him, we might be able to find a cure for terminal illnesses and be able to make the most of the resources we have been given. We humans just have to use it responsibly. "With great power comes great responsibility", after all.

If we can find a way to keep our medicines affective and put food alerts on GM foods, along with other preventive measures put in place, we can explore and enjoy science, while being safe.

We have created "disease fighting eggs" and ecobeneficial pastures and cows with genetic engineering. Who says we can not do more? If we make sure to use it wisely, the future of genetic engineering may have an important role in the modern world ..

The Biogen Kenneth Murray dejo un Legado

The Biogen Kenneth Murray dejo un Legado :

Don Seiffert
Associate Editor MHT-
Boston Business Journal
Email
When Kenneth Murray, a professor at the University of Edinburgh in the 1970s, was involved in the founding of a company that later became Biogen Idec (Nasdaq: BIIB), was criticized by his peers as engaging in "activities repugnant. "
Phillip Sharp, a 1993 Nobel molecular biologist and co-founder of Biogen in 1978, along with Murray, told Mass High Tech that even here in the U.S., it was rare that a researcher is involved in the industry, although not was another way for drugs that are available for patients.
"There were few, if any, the MIT faculty involved in biotechnology at all" he said. "In fact, there were only invented the word."
Murray died earlier this month at age 82 at his home in Edinburgh, but the lives of patients who have saved and improved through the company he helped create will not be soon forgotten. Sharp, who is 69 years old and lives in Newton, Massachusetts, says he knew Murray in the 1970s because they were scientists working on recombinant DNA and genetics, and they met at international meetings. They, along with six others, co-founder of Biogen based on two initial drugs: interferon alpha for certain types of leukemia and hepatitis C, and hepatitis B vaccine, which is based on the investigation of Murray.
The hepatitis B vaccine Biogen was approved for use in 1982 and formed the revenue stream Biogen earlier, according to a brief biography written by Biogen. Before that, the vaccine was available, but very limited, and it had to be done with the blood of hepatitis B. Murray has found a way to create synthetically, and the resulting patent was cited in 2002 by IP Worldwide magazine as one of the 10 patents that changed the world, according to the company.

Genetic engineering standby in citrus disease battle

Genetic engineering standby in citrus disease battle : 
A pandemic is destroying Florida orange groves. The disease, citrus greening, also is spreading citrus plantations in Texas and California, threatening more than $ 3 billion a year industry.
If left unaddressed, the entire U.S. citrus industry would disappear and, as Senator Bill Nelson of Florida, "We're going to end up paying $ 5 for an orange - and we have to be one imported from somewhere else."

Citrus Greening is spread by bacteria that block nutrients trees "and the water channels and avoid the fruit ripens.

"It's like choking the tree from the inside out," said David Banda, a state molecular biologist at the University of Washington and biochemist who is collaborating with a broad interdisciplinary team to fight the disease.

The disease spreads Insects

The bacteria are hosted and spread by an insect related to aphids and whiteflies called the Asian citrus psyllid (pronounced sill-id). It is believed that the disease has spread in China in the 2000s. Citrus greening has destroyed the citrus industry in Jamaica.

The invasive psyllids citrus trees pierce with a needle-shaped nozzle, similar to the way a mosquito infects its victims. As supplies of water and nutrients from the tree, the psyllid injected disease-causing bacteria, which then spread to the rest of the plant.

To combat this aggressive disease, the U.S. Department of Agriculture has funded a multi-faceted initiative, multi-institutional participation of more than 40 researchers located in various states. Scientists are studying the ecological consequences of the disease, the biology of the citrus trees, insects and the mechanism by which the bacteria spread insect.
Want access to the latest agricultural news every day? Newspaper Sign up for email newsletter Farm West.

Pesticides have been of some use in controlling psyllids but researchers are concerned that insects develop resistance. And biocontrol - siccing good insects to prey on the poor - have proved ineffective because the psyllid just inbred predators.

That's where David Gang enters the picture.

Altering the insect

The gang laboratory at the Institute of Biological Chemistry WSU focuses on the use of new technologies such as genomics and proteomics to study the mechanisms of plant defense, particularly the chemicals that help plants survive and fight pathogens and pests. The project, funded by the USDA, Gang and colleagues isolated and sequenced the genes that are expressed in the psyllids, as they feed on citrus plants.

Thursday, 2 May 2013

History Of Human Revolution : Pikaya

History Of Human Revolution


                                  Pikaya
"Pikaya" is the first elies that had Spinal Cord. It showed it's existence before 60,000 crore  years. The scientist research said that "Pikaya was the first Human Ansistor " - Dr Madurima

NEWS : Gene sequencing project finds new mutations of the blame for most subtypes of brain tumors


Gene sequencing project finds new mutations of the blame for most subtypes of brain tumors : 


MEMPHIS, Tenn., April 14, 2013 /PRNewswire-USNewswire/ -- The St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project has identified mutations responsible for more than half of a subtype of childhood brain tumor that takes a high toll on patients. Researchers also found evidence the tumors are susceptible to drugs already in development.
The study focused on a family of brain tumors known as low-grade gliomas (LGGs). These slow-growing cancers are found in about 700 children annually in the U.S., making them the most common childhood tumors of the brain and spinal cord. For patients whose tumors cannot be surgically removed, the long-term outlook remains bleak due to complications from the disease and its ongoing treatment. Nationwide, surgery alone cures only about one-third of patients.
Using whole genome sequencing, researchers identified genetic alterations in two genes that occurred almost exclusively in a subtype of LGG termed diffuse LGG. This subtype cannot be cured surgically because the tumor cells invade the healthy brain. Together, the mutations accounted for 53 percent of the diffuse LGG in this study. Researchers also demonstrated that one of the mutations, which had not previously been linked to brain tumors, caused tumors when introduced into the glial brain cells of mice.
The findings appear in the April 14 advance online edition of the scientific journal Nature Genetics.

"This subtype of low-grade glioma can be a nasty chronic disease, yet prior to this study we knew almost nothing about its genetic alterations," said David Ellison, M.D., Ph.D., chair of the St. Jude Department of Pathology and the study's corresponding author. The first author is Jinghui Zhang, Ph.D., an associate member of the St. Jude Department of Computational Biology.

The Pediatric Cancer Genome Project is using next-generation whole genome sequencing to determine the complete normal and cancer genomes of children and adolescents with some of the least understood and most difficult to treat cancers. Scientists believe that studying differences in the 3 billion chemical bases that make up the human genome will provide the scientific foundation for the next generation of cancer care.

"We were surprised to find that many of these tumors could be traced to a single genetic alteration," said co-author Richard K. Wilson, Ph.D., director of The Genome Institute at Washington University School of Medicine in St. Louis. "This is a major pathway through which low-grade gliomas develop and it provides new clues to explore as we search for better treatments."

The study involved whole genome sequencing of 39 paired tumor and normal tissue samples from 38 children and adolescents with different subtypes of LGG and related tumors called low-grade glioneuronal tumors (LGGNTs). Although many cancers develop following multiple genetic abnormalities, 62 percent of the 39 tumors in this study stemmed from a single genetic alteration.

Previous studies have linked LGGs to abnormal activation of the MAPK/ERK pathway. The pathway is involved in regulating cell division and other processes that are often disrupted in cancer. Until now, however, the genetic alterations involved in driving this pathway were unknown for some types of LGG and LGGNT.

This study linked activation in the pathway to duplication of a key segment of the FGFR1 gene, which investigators discovered in brain tumors for the first time. The segment is called a tyrosine kinase domain. It functions like an on-off switch for several cell signaling pathways, including the MAPK/ERK pathway. Investigators also demonstrated that experimental drugs designed to block activity along two altered pathways worked in cells with the FGFR1 tyrosine kinase domain duplication. "The finding suggests a potential opportunity for using targeted therapies in patients whose tumors cannot be surgically removed," Ellison said.

Researchers also showed that the FGFR1 abnormality triggered an aggressive brain tumor in glial cells from mice that lacked the tumor suppressor gene Trp53. 

Whole-genome sequencing found previously undiscovered rearrangements in the MYB and MYBL1 genes in diffuse LGGs. These newly identified abnormalities were also implicated in switching on the MAPK/ERK pathway. Researchers checked an additional 100 LGGs and LGGNTs for the same FGFR1, MYB and MYBL1mutations. Overall, MYB was altered in 25 percent of the diffuse LGGs, and 24 percent had alterations in FGFR1. Researchers also turned up numerous other mutations that occurred in just a few tumors. The affected genes included BRAF, RAF1, H3F3A, ATRX, EP300, WHSC1 and CHD2.

"The Pediatric Cancer Genome Project has provided a remarkable opportunity to look at the genomic landscape of this disease and really put the alterations responsible on the map. We can now account for the genetic errors responsible for more than 90 percent of low-grade gliomas," Ellison said.  "The discovery that FGFR1 and MYB play a central role in childhood diffuse LGG also serves to distinguish the pediatric and adult forms of the disease."

The other authors are Gang Wu, Ruth Tatevossian, James Dalton, Bo Tang, Wilda Orisme, Chandanamali Punchihewa, Ibrahim Qaddoumi, Frederick Boop, Matthew Parker, Ryan Lee, Robert Huether, Xiang Chen, Erin Hedlund, Panduka Nagahawatte, Michael Rusch, Kristy Boggs, Jinjun Cheng, Jared Becksfort, Jing Ma, Guangchun Song, Yongjin Li, Lei Wei, Jianmin Wang, Sheila Shurtleff, John Easton, David Zhao, Bhavin Vadodaria, Heather Mulder, Chunlao Tang, Charles Mullighan, Amar Gajjar, Richard Kriwacki, Richard Gilbertson, James Downing and Suzanne Baker, all of St. Jude; Claudia Miller, formerly of St. Jude; Charles Lu, Cyriac Kandoth, Li Ding, Robert Fulton, Lucinda Fulton, David Dooling, Kerri Ochoa and Elaine Mardis, all of Washington University; and Denise Sheer of Queen Mary University of London.
The research was funded in part by the Pediatric Cancer Genome Project, including Kay Jewelers, a lead partner; a grant (CA096832) from the National Institutes of Health; and ALSAC.

St. Jude Children's Research Hospital St. Jude Children's Research Hospital is internationally recognized for its pioneering research and treatment of children with cancer and other life-threatening diseases. The hospital's research has helped push overall survival rates for childhood cancer from less than 20 percent when the institution opened to almost 80 percent today. It is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children, and no family ever pays St. Jude for anything. For more information, 

Washington University School of Medicine Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.



NEWS : Gene sequencing helps identify drug resistant malaria

Gene sequencing helps identify drug-resistant malaria : 


Know your enemy and the fight becomes easier. Researchers have pinpointed three sub-populations of the malaria parasite Plasmodium falciparum that appear to be a major force in drug resistance. The findings could help efforts to track the spread of resistant malaria in future. The first signs of resistance to the front-line malarial drug artemisinin emerged in Cambodia in 2009. If this resistance spreads worldwide, it will leave people with malaria without an effective drug to treat their illness.  Olivo Miotto at the University of Oxford, and a large international team, studied the genomes of 825 malarial parasites from south-east Asia and west Africa in an effort to understand why some parasite populations become resistant.  The work identified three drug-resistant P. falciparum sub-populations in western Cambodia that were different from each other, and different from populations in eastern Cambodia, neighbouring countries and west Africa. "For the first time we have identified the emergence of sub-populations associated with a drug resistance to artemisinin," says Miotto.

         
Why Cambodia?
Cambodia is thought to be a breeding ground for resistance. Past drug therapies in the country encouraged sole use of artemisinin to treat malaria, which could have been a factor.  Demographic factors could also have played a part: the Khmer Rouge regime of the late 1970s left the country with poor infrastructure and small, isolated communities. In those circumstances, a resistant strain can replicate itself quickly through inbreeding: in west Africa there is more outbreeding, which may slow the spread of resistance there. "This research sheds light on the evolution of artemisinin resistance and suggests that the situation is more complicated than we thought," says Lisa Ranford-Cartwright from the University of Glasgow, UK, who was nt involved in the study.  A full understanding of the mechanisms that build resistance is still out of reach, but the new study does mean researchers will be able to use genetic tests to identify any geographical spread of the three resistant sub-populations in future. "Being able to detect if there is a sudden explosion of one particular type of parasite will indicate if something is going wrong," Miotto says.

Recently Report: The Genetic Revolution

                 The Genetic Revolution
On DNA Day, we celebrate the achievements that are ushering in the era of personalized genetic medicine

                                                                  The Genetic Revolution
                             60 years ago this month, researchers James Watson and Francis Crick described the double helix shape of DNA. This breakthrough allowed geneticists to study how an organism’s physical characteristics are encoded in the DNA molecule, and how living creatures pass down traits to their offspring. Ten years ago this month, researchers completed sequencing the human genome, putting the roughly 3 billion letters that make up a molecule of human DNA in order. The Human Genome Project took more than a decade and cost about US $3 billion. With this comprehensive map, researchers can more easily study how our genes determine our medical fates. On April 25, researchers celebrate DNA Day to mark the accomplishments of the past, and to marvel at the progress made since those historic milestones. Today, fast and cheap machines enable scientists to sequence the genomes of thousands of people in research projects devoted to complex diseases like cancer and heart disease. Soon, such whole-genome scans may be a routine part of medicine. IEEE Spectrum explores the new field of personalized genetic medicine with a package of articles, radio pieces, and blog posts. Happy DNA Day!

NEWS : Stress Syndrome Linked to genetic defect Pig

   Stress Syndrome Linked to genetic defect Pig :


Pig Stress Syndrome
A defect in a gene called dystrophin is the cause of a newly discovered stress syndrome in pigs, U.S. Department of Agriculture (USDA) scientists have found. Stress-related issues like transportation cost the U.S. swine industry an estimated $50 million a year. Producers as well as researchers have long suspected that undetected stress-related syndromes are affecting the health and well-being of pigs. This notion was confirmed when scientists at the Agricultural Research Service (ARS) Roman L. Hruska U.S. Meat Animal Research Center (USMARC) in Clay Center, Neb., discovered a stress syndrome in two 3-month-old male siblings that died after being transported from one facility to another. The novel syndrome is different than the classical porcine stress syndrome, which was eliminated from U.S. swine herds years ago. Molecular biologist Dan Nonneman and his colleagues in the USMARC Reproduction Research Unit mapped the stress disorder to a genetic mutation in dystrophin. Mutations in dystrophin, which cause DMD—Duchenne muscular dystrophy—are associated with muscle weakness that can lead to death. To map the disease, scientists re-mated the original parents of the affected siblings to produce additional litters. The 250 offspring, which included 49 affected piglets, were genotyped, and one chromosomal region containing the dystrophin gene was associated with the syndrome. Piglets affected by the syndrome had an abnormal heart rate when treated with an anesthesia and monitored. The heart rate of unaffected pigs undergoing the same treatments remained steady. Animals with the stress condition had half as much dystrophin protein as their unaffected siblings. Pigs suspected of having the syndrome also had three times as much creatine phosphokinase, an enzyme used to monitor heart and muscle diseases. The gene is located on the X chromosome, and the syndrome is found primarily in males that inherit the affected X chromosome from their mother. Animals seem more susceptible at two months of age, a time when piglets are transported from nursery to grower facilities. Read more about this research in the April 2013 issue of Agricultural Research magazine.
ARS is USDA's chief intramural scientific research agency, and this research supports USDA's priority of promoting international food security.

NEWS :CIHR Café Scientifique: Genetic Testing and You, April 15.

CIHR Café Scientifique: Genetic Testing and You, April 15.: 

What does it mean when you undergo genetic testing? Do you need this test? What does the information mean and how will it be used? Who do you share this information with? Can this information hurt your access to insurance, credit or a job? How can it help you? Join the discussion and hear from a panel of experts that include Timothy Caulfield, Professor, Faculty of Law and School of Public Health, University of Alberta; Bev Heim-Myers, Chair, The Canadian Coalition for Genetic Fairness; Gail Ouellette, Directrice, Regroupement québécois des maladies orphelines; and Frank Zinatelli, Vice-president and general counsel, Canadian Life and Health Insurance Association.
                                                                            Monday, April 15, 2013

NEWS : Gene patents hurt everyone


Gene patents hurt everyone :

 Most court cases involving patent law are corporate battles, with one company suing another for infringing on its intellectual property rights and, therefore, profits. Big companies fighting over big money can seem painfully irrelevant, especially when so many of us are simply struggling to get by. But the case coming before the U.S. Supreme Court on Monday challenging two patents is a different animal, with enormous implications for both our health and shared humanity. The patents in question are on two human genes, BRCA1 and BRCA2, commonly referred to as the “breast cancer genes.” We all have these genes in the cells of our bodies, but certain variants in some people significantly increase the risk of breast and ovarian cancer. Learning whether you have these risk-elevating mutations can be important because it gives you the opportunity to consider increased surveillance (such as cancer screenings and mammography) and even surgery to remove healthy organs. The patents give one biotechnology company, Myriad Genetics Inc., sweeping control of the two genes. Myriad’s monopoly harms women’s health, impedes cancer research and raises important ethical questions about control over the human genome. Myriad’s patents cover both the normal versions of the genes and all mutations and rearrangements within them. This monopoly has prevented other scientists and doctors from using the BRCA1 and BRCA2 genes in research, medicine, diagnosis and treatment. With revenue from the patents approaching half a billion dollars a year, Myriad frequently restricts access to these genes. It sends cease-and-desist notices to prevent other researchers from working with them. Myriad’s strict patent enforcement means its test is the only available one to determine whether a woman has a genetic variant that increases her risk of cancer. Women cannot get a second opinion about the results, even when faced with a decision about removing healthy organs to reduce their cancer risk. And too many women cannot even have the test because it is too expensive. Furthermore, because Myriad’s test focuses on already-identified variants, some women, especially women of color, are more likely to get ambiguous results. They are told they have a genetic variant but that Myriad doesn’t know whether it increases their risk of cancer. The lawsuit before the Supreme Court this week has united women’s health organizations, research groups, genetic counselors and breast cancer patients. The American Civil Liberties Union and the Public Patent Foundation, the lead plaintiffs, make a straightforward argument (full disclosure: Breast Cancer Action is also a plaintiff; Center for Genetics and Society has signed several briefs): U.S. case law and patent statute plainly say that patents can be awarded only for human inventions. Genes are not inventions but products of nature. You can’t patent the sun; you can’t patent a new species of insect you find in a forest; you can’t patent the speed of light. And you cannot patent human genes. Beyond U.S. patent law lie broader questions: Should we treat human genes as private property to be exploited for profit rather than shared resources managed in the public interest? Should we allow corporate ownership to penetrate deeply into areas previously considered outside the commercial realm? Several international organizations have taken up these questions, declaring the human genome part of the “commons” – akin to the moon and the air we breathe. The Universal Declaration on the Human Genome and Human Rights, ratified by the U.N. General Assembly in 1998, states that the human genome “is the heritage of humanity” and “in its natural state shall not give rise to financial gains.” In 1999, the Parliamentary Assembly of the Council of Europe declared that “neither plant-, animal- nor human-derived genes, cells, tissue or organs can be considered as inventions, nor be subject to monopolies granted by patents.” The World Medical Association, an umbrella for 84 national medical associations, states that “human genes must be seen as mankind’s common heritage.”
Despite these strong declarations and the robust legal precedent for limiting patent protection to inventions, much of the human genome has been patented in a rush to profit from the incredible amount of information our genetic makeup holds, often to the detriment of our health. We believe there has been a misapplication of patent law, as acknowledged by the U.S. solicitor general’s amicus brief on our behalf. It was not always this way, and it need not stay this way. In 1955, Jonas Salk, who had invented the polio vaccine, was asked who owned the patent on the vaccine. “The people,” he replied. “There is no patent. Could you patent the sun?”
A ruling in favor of the plaintiffs in this landmark case could effectively outlaw human gene patents. It would be a victory for all who put the public’s health and interests above efforts to privatize what all of us should share. And it would restore our genomic heritage, the very DNA in our bodies, to the rightful owners: the people.